Prevent Cancer Foundation welcomes largest-ever Corporate Membership Program cohort in 2026
ZUR SOFORTIGEN VERÖFFENTLICHUNG
Kyra Meister
703-836-1746
kyra.meister@preventcancer.org
Alexandria, Va. – The Prevent Cancer Foundation® is proud to welcome 23 leading companies to its Corporate Membership Program. Together, they make up the program’s largest-ever cohort, strengthening a growing network of business leaders dedicated to reducing the impact of cancer through prevention and early detection.
Program members receive exclusive access to Foundation events and resources while providing vital support for the Foundation’s work in education, outreach, advocacy and community. Through collaboration and the exchange of ideas, members help advance cancer prevention and early detection efforts, empowering people to take steps that can improve health outcomes and save more lives.
“Our corporate partners play a vital role in advancing cancer prevention and early detection nationwide,” said Jody Hoyos, CEO of the Prevent Cancer Foundation. “We’re proud to work alongside companies that share our vision of a world where cancer is preventable, detectable and beatable for all.”
The 2026 class of corporate members, as of the date of this publication, include:
Silver members
- Abbott
- Bristol Myers Squibb
- Hologic
- Pfizer
- PhRMA
Bronze members
- AbbVie
- Astellas
- AstraZeneca
- Boehringer Ingelheim
- Eisai
- Eli Lilly & Co
- Exelixis
- Freenome
- Genentech
- Geneoscopy
- GSK
- Guardant Health
- Merck
- Mercy BioAnalytics
- Natera
- Novartis
- Sanofi
The Corporate Membership Program is open to companies who support the Foundation’s mission: Stopping Cancer. Saving Lives. To learn more or inquire about joining, contact Anne Potter, Senior Director of Corporate and Foundation Relations, at anne.potter@prevencancer.org.
###
Über die Prevent Cancer Foundation®
Die Stiftung Prevent Cancer® is the only U.S.-based nonprofit organization solely dedicated to cancer prevention and early detection. Through research, education, advocacy and community, we have helped countless people avoid a cancer diagnosis or detect their cancer early enough to be successfully treated. We are driven by a vision of a world where cancer is preventable, detectable and beatable for all.
Die Stiftung stellt sich der Herausforderung, die Zahl der Krebstoten bis 2035 um 401 TP3T zu senken. Um dieses Ziel zu erreichen, haben wir uns verpflichtet, 1 TP4T20 Millionen in innovative Technologien zur Krebsfrüherkennung und zur Verbesserung des Multi-Krebs-Screenings zu investieren, 1 TP4T10 Millionen in die Ausweitung des Zugangs zu Krebsscreenings und Impfungen auf medizinisch unterversorgte Gemeinden und 1 TP4T10 Millionen in die Aufklärung der Öffentlichkeit über Screening- und Impfmöglichkeiten.
Für weitere Informationen, besuchen Sie bitte www.preventcancer.org.